ECSP067024A - Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos - Google Patents

Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos

Info

Publication number
ECSP067024A
ECSP067024A EC2006007024A ECSP067024A ECSP067024A EC SP067024 A ECSP067024 A EC SP067024A EC 2006007024 A EC2006007024 A EC 2006007024A EC SP067024 A ECSP067024 A EC SP067024A EC SP067024 A ECSP067024 A EC SP067024A
Authority
EC
Ecuador
Prior art keywords
disorders
sexual
disorder
sexual dysfunction
compounds
Prior art date
Application number
EC2006007024A
Other languages
English (en)
Inventor
Charlotte Moira Norfor Allerton
David Hepworth
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411810A external-priority patent/GB0411810D0/en
Priority claimed from GB0415455A external-priority patent/GB0415455D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP067024A publication Critical patent/ECSP067024A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I), que son una clase de agonistas de dopamina, más particularmente una clase de agonistas que son selectivos por D3 frente a D2. Estos compuestos son útiles para el tratamiento y/o la prevención de disfunción sexual, por ejemplo, disfunción sexual femenina (DSF), en particular trastorno de la excitación sexual femenina (TESF), trastorno del deseo sexual hipoactivo (TDSH, falta de interés en el sexo), trastorno orgásmico femenino (TOF, incapacidad de alcanzar el orgasmo) y disfunción sexual masculina, particularmente disfunción eréctil masculina (DEM). La disfunción sexual masculina como se designa en la presente memoria se pretende que incluya trastornos eyaculatorios tales como eyaculación precoz, anorgasmia (incapacidad de conseguir el orgasmo) o trastornos del deseo tales como trastorno del deseo sexual hipoactivo (TDSH, falta de interés en el sexo). Estos compuestos son también útiles para tratar trastornos neuropsiquiátricos y trastornos neurodegenerativos.
EC2006007024A 2004-05-26 2006-11-24 Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos ECSP067024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411810A GB0411810D0 (en) 2004-05-26 2004-05-26 New indazole and indolone derivatives and their use as pharmaceuticals
GB0415455A GB0415455D0 (en) 2004-07-09 2004-07-09 New indazole and indolone derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ECSP067024A true ECSP067024A (es) 2006-12-29

Family

ID=35219654

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007024A ECSP067024A (es) 2004-05-26 2006-11-24 Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos

Country Status (25)

Country Link
EP (1) EP1753763B1 (es)
JP (2) JP4093588B2 (es)
AP (1) AP2006003823A0 (es)
AR (1) AR049191A1 (es)
AT (1) ATE404560T1 (es)
AU (1) AU2005247696A1 (es)
BR (1) BRPI0511533A (es)
CA (1) CA2568050A1 (es)
CR (1) CR8772A (es)
DE (1) DE602005008954D1 (es)
EA (1) EA200601985A1 (es)
EC (1) ECSP067024A (es)
ES (1) ES2308492T3 (es)
GT (1) GT200500118A (es)
IL (1) IL179365A0 (es)
MA (1) MA28606B1 (es)
MX (1) MXPA06013759A (es)
NL (1) NL1029128C2 (es)
NO (1) NO20065328L (es)
PA (1) PA8635001A1 (es)
PE (1) PE20060289A1 (es)
SV (1) SV2005002128A (es)
TW (1) TW200607500A (es)
UY (1) UY28918A1 (es)
WO (1) WO2005116027A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2860B1 (en) 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
CA2860453C (en) * 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
WO1998035942A1 (en) * 1997-02-18 1998-08-20 American Home Products Corporation 4-aminoethoxyindazole derivatives
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
RS51442B (sr) * 2002-12-10 2011-04-30 Pfizer Inc. Derivati morfolina koji se upotrebljavaju kao agonisti dopamina u tretmanu i.a. seksualne disfunkcije

Also Published As

Publication number Publication date
NL1029128C2 (nl) 2006-06-14
DE602005008954D1 (de) 2008-09-25
PE20060289A1 (es) 2006-04-22
CA2568050A1 (en) 2005-12-08
BRPI0511533A (pt) 2008-01-02
WO2005116027A2 (en) 2005-12-08
EP1753763B1 (en) 2008-08-13
AU2005247696A1 (en) 2005-12-08
UY28918A1 (es) 2005-12-30
PA8635001A1 (es) 2006-05-16
JP2008500329A (ja) 2008-01-10
JP2008074874A (ja) 2008-04-03
AP2006003823A0 (en) 2006-12-31
WO2005116027A3 (en) 2006-04-13
TW200607500A (en) 2006-03-01
JP4093588B2 (ja) 2008-06-04
NL1029128A1 (nl) 2005-11-30
CR8772A (es) 2006-12-13
IL179365A0 (en) 2007-03-08
MA28606B1 (fr) 2007-05-02
EP1753763A2 (en) 2007-02-21
ES2308492T3 (es) 2008-12-01
GT200500118A (es) 2006-01-10
EA200601985A1 (ru) 2007-04-27
SV2005002128A (es) 2005-12-13
AR049191A1 (es) 2006-07-05
MXPA06013759A (es) 2007-02-08
ATE404560T1 (de) 2008-08-15
NO20065328L (no) 2006-12-18

Similar Documents

Publication Publication Date Title
MX2022010274A (es) Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
CR20180029A (es) Inhibidores peotídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
CO6430487A2 (es) Anticuerpos anti-her
MX2011013260A (es) Apomorfina sublingual.
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2011001712A1 (es) Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina.
CL2012002905A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
CY1116710T1 (el) Σκευασματα επικαλυμμενα με λεπτο υμενιο για χορηγηση απο στοματος που περιλαμβανουν δαποξετινη και ταδαλαφιλη
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CL2016001167A1 (es) Uso de un implante bioerosionable para tratar enfermedades oculares.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
CL2012002954A1 (es) Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros.
ECSP067029A (es) Nuevos derivados de aminopiridina y su uso como farmacos
ECSP067024A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
DOP2005000093A (es) Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
MX2022000356A (es) Compuesto para tratamiento de combinacion.
DOP2005000095A (es) Nuevos derivados de aminopiridina y su uso como farmacos
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido
PH12015502598A1 (en) Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
MX2012014968A (es) Dosis fija de una combinacion farmaceutica de tadalafilo y dapoxetina.